The Serum Institute of India (SII) has submitted the data to DCGI’s Subject Expert Committee (SEC).In previous meeting by SEC Serum Institute of India and bharat biotech was asked to submit more data about clinical trials, reports IANS
The SEC can do a meeting on Serum Institute of India’s emergency authorisation for Covishield vaccine at the end of this week.
